Use of dermal injection of activated protein C for treatment of large chronic wounds secondary to pyoderma gangrenosum

Clinical and Experimental Dermatology

Volumn 39, Issue 7, 2014, Pages 785-790

  Kapila, S ^a   Reid, I ^a   Dixit, Shreya ^a   Fulcher, G ^a   March, L ^b   Jackson, C ^a   Cooper, A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; PREDNISONE; ANTIINFLAMMATORY AGENT; PROTEIN C; RECOMBINANT PROTEIN;

AGED; ARTICLE; CASE REPORT; DEBRIDEMENT; DISEASE CONTROL; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAL PHOTOGRAPHY; PAIN ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PATIENT SELECTION; PRIORITY JOURNAL; PROTHROMBIN TIME; PYODERMA GANGRENOSUM; RECOMMENDED DRUG DOSE; SKIN GRAFT; SKIN ULCER; ULCER; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; INTRADERMAL DRUG ADMINISTRATION; WOUND HEALING;

AGED; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; MALE; PROTEIN C; PYODERMA GANGRENOSUM; RECOMBINANT PROTEINS; SKIN ULCER; WOUND HEALING;

EID: 84927562177     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12361     Document Type: Article

References (22)

1. Cox NH, Jorizzo JL, Bourke JF, Savage COS. Vasculitis, neutrophilic dermatoses and related disorders. In: Rook's Textbook of Dermatology, 8th edn (Burns T, Breathnach S, Cox N, Griffiths C, eds). Oxford: Blackwell Publishing, 2010; 50.64-50.74.
2. Powell FC, Hackett BC. Pyoderma gangrenosum. In: Fitpatrick's Dermatology in General Medicine, 8th edn (Wolff K, Goldsmith LA, Katz SI et al., eds). New York: McGraw-Hill Companies Inc, 2008; 296-302.
3. Mekkes JR, Loots MAM, Van Der Wal AC, Bos JD. Causes, investigation and treatment of leg ulceration. Br J Dermatol 2003; 148: 388-401.
4. Saigal R, Singh Y, Mittal M et al. Pyoderma gangrenosum. J Assoc Physicians India 2010; 58: 378-83.
5. Bhat RM, Nandakishore B, Sequeira FF et al. Pyoderma gangrenosum: An Indian perspective. Clin Exp Dermatol 2010; 36: 242-7.
6. Sarkar PK, Ballantyne S. Management of leg ulcers. Postgrad Med J 2000; 76: 674-82.
7. Brooklyn T, Dunhill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 333: 181-4.
8. Rozen SM, Nahabedian MY, Manson PN. Management strategies for pyoderma gangrenosum: Case studies and review of literature. Ann Plast Surg 2001; 47: 310-15.
9. Callen JP. Cutaneous vasculitis and other neutrophilic dermatoses. Curr Opin Rheumatol 1993; 5: 33-40.
10. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: A comprehensive review. Am J Clin Dermatol 2012; 13: 191-211.
11. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). Dermatol Ther 2011; 24: 273-84.
12. Yuksel M, Okajima K, Uchiba M et al. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88: 267-73.
13. Jackson C, Whitmont K, Tritton S et al. New therapeutic applications for the anticoagulant, activated protein C. Expert Opin Biol Ther 2008; 8: 1-14.
14. McCaffery M, Pasero C. Pain: Clinical Manual. St. Louis: Mosby Inc., 1999; 16.
15. Miller J, Yentzer BA, Clark A et al. Pyoderma gangrenosum: A review and update on new therapies. J Am Acad Dermatol 2010; 62: 646-54.
16. Wong D, Baker C. Pain in children: Comparison of assessment scales. Pediatr Nurs 1988; 14: 9-17.
17. Whitmont K, Reid I, Tritton S et al. Treatment of chronic leg ulcers with topical activated protein C. Arch Dermatol 2008; 144: 1479-83.
18. Wijewardena A, Vandervord E, Lajevardi SS et al. Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopaedic wounds. Int J Low Extrem Wounds 2011; 10: 146-51.
19. Xue M, Campbell D, Sambrook PN. Endothelial protein C Receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. J Invest Dermatol 2005; 125: 1279-85.
20. Xue M, Campbell D, Jackson CJ. Protein C is an autocrine growth factor for human skin keratinocytes. J Biol Chem 2007; 282: 13610-16.
21. Bennett ML, Jackson JM, Jorizzo JL et al. Pyoderma gangrenosum - A comparison of typical and atypical form with emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 2000; 79: 37-46.
22. Whitmont K, McKelvey KJ, Fulcher G et al. Treatment of chronic diabetic lower leg ulcers with activated protein C: A randomized placebo-controlled, double-blind pilot clinical trial. Int Wound J 2013; doi: 10.1111/iwj.12125. [Epub ahead of print].